Pembrolizumab Plus Chemotherapy for Cervical Cancer

Дата публикации: 10-09-2026 00:00:00

This exploratory analysis of the KEYNOTE-826 randomized clinical trial evaluates clinically relevant 5-year follow-up results.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer	0	8.64	01-08-2026
2	Neoadjuvant Immune Checkpoint Inhibitors in Early Breast Cancer	0	7.64	01-10-2024
3	PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	0	10.08	17-09-2026
4	Pathological response and exploratory assessment of pretreatment PD-L1 combined positive score after four cycles of neoadjuvant pembrolizumab plus chemotherapy in locally advanced head and neck squamous cell carcinoma: a retrospective cohort study	0	13.96	07-08-2026
5	Is Antigen-Specific Immunotherapy a New Frontier in HPV-Initiated Head and Neck Cancer?	0	10.94	17-09-2026
6	Checkpoint Inhibitors Plus Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors	0	4.57	01-09-2023
7	Cost-Effectiveness of Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer	0	7	02-07-2026
8	Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions	0	5	23-06-2026
9	Time to Sustained CEA Elevation From Start of First-Line Therapy Predicts Initial Treatment Efficacy and Clinical Outcomes in Lung Adenocarcinoma	0	17.69	20-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 14.76. Источник: jamanetwork.com.